$2.46T
Total marketcap
$205.41B
Total volume
BTC 50.07%     ETH 15.65%
Dominance

UCB SA UCBJY Stock

58.22 USD {{ price }} 2.140353% {{change_pct}}%
Exchange
Other OTC
Market Cap
22.1B USD
LOW - HIGH [24H]
57.8 - 58.52 USD
VOLUME [24H]
5K USD
{{ volume }}
P/E Ratio
60.64
Earnings per share
0.96 USD

UCB SA Price Chart

UCB SA UCBJY Financial and Trading Overview

UCB SA stock price 58.22 USD
Previous Close 45.51 USD
Open 46.03 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 46.02 - 46.53 USD
52 Week Range 32.82 - 48.45 USD
Volume 5.08K USD
Avg. Volume 7K USD
Market Cap 17.64B USD
Beta (5Y Monthly) 0.352107
PE Ratio (TTM) 39.76923
EPS (TTM) 0.96 USD
Forward Dividend & Yield 0.73 (1.60%)
Ex-Dividend Date May 1, 2023
1y Target Est N/A

UCBJY Valuation Measures

Enterprise Value 19.21B USD
Trailing P/E 39.76923
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 3.239161
Price/Book (mrq) 1.9465768
Enterprise Value/Revenue 3.527
Enterprise Value/EBITDA 16.881

Trading Information

UCB SA Stock Price History

Beta (5Y Monthly) 0.352107
52-Week Change 13.37%
S&P500 52-Week Change 20.43%
52 Week High 48.45 USD
52 Week Low 32.82 USD
50-Day Moving Average 46.25 USD
200-Day Moving Average 40.95 USD

UCBJY Share Statistics

Avg. Volume (3 month) 7K USD
Avg. Daily Volume (10-Days) 6.03K USD
Shares Outstanding 379.19M
Float 240.3M
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0.0050%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 1.33
Trailing Annual Dividend Yield 2.92%
5 Year Average Dividend Yield 154.00%
Payout Ratio 0.60400003
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 7.67%
Operating Margin (ttm) 10.99%
Gross Margin 69.26%
EBITDA Margin 20.89%

Management Effectiveness

Return on Assets (ttm) 2.48%
Return on Equity (ttm) 4.81%

Income Statement

Revenue (ttm) 5.45B USD
Revenue Per Share (ttm) 14.36 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 3.77B USD
EBITDA 1.14B USD
Net Income Avi to Common (ttm) 420M USD
Diluted EPS (ttm) 1.17
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 946M USD
Total Cash Per Share (mrq) 2.5 USD
Total Debt (mrq) 2.9B USD
Total Debt/Equity (mrq) 32 USD
Current Ratio (mrq) 1.062
Book Value Per Share (mrq) 23.9035

Cash Flow Statement

Operating Cash Flow (ttm) 1.12B USD
Levered Free Cash Flow (ttm) 749.37M USD

Profile of UCB SA

Country United States
State N/A
City Brussels
Address AllEe de la Recherche, 60
ZIP 1070
Phone 32 2 559 99 99
Website https://www.ucb.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 8108

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Q&A For UCB SA Stock

What is a current UCBJY stock price?

UCB SA UCBJY stock price today per share is 58.22 USD.

How to purchase UCB SA stock?

You can buy UCBJY shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for UCB SA?

The stock symbol or ticker of UCB SA is UCBJY.

Which industry does the UCB SA company belong to?

The UCB SA industry is Biotechnology.

How many shares does UCB SA have in circulation?

The max supply of UCB SA shares is 379.55M.

What is UCB SA Price to Earnings Ratio (PE Ratio)?

UCB SA PE Ratio is 60.64583600 now.

What was UCB SA earnings per share over the trailing 12 months (TTM)?

UCB SA EPS is 0.96 USD over the trailing 12 months.

Which sector does the UCB SA company belong to?

The UCB SA sector is Healthcare.